Alpha thalassemia is an inherited blood disorder where your body doesn’t produce enough of a key protein in hemoglobin, the molecule inside red blood cells that carries oxygen. Everyone has four genes responsible for making this protein (called alpha-globin), and alpha thalassemia occurs when one or more of those genes are missing or nonfunctional. The severity ranges from completely unnoticeable to life-threatening, depending on how many genes are affected.
How Alpha Thalassemia Happens
Hemoglobin is built from two types of protein chains: alpha-globin and beta-globin. You inherit two alpha-globin genes from each parent, giving you four total. These genes sit on chromosome 16, and when one or more are deleted or mutated, your red blood cells end up smaller and paler than normal because they can’t pack in enough hemoglobin.
About 90% of alpha thalassemia cases are caused by outright deletions of gene segments rather than smaller mutations. In rarer cases, a single-letter change in the genetic code disrupts function. The condition is especially common in people of Southeast Asian, Southern Chinese, African, and Mediterranean descent, where carrier rates can be quite high.
The Four Types, by Gene Count
The number of affected genes determines which form you have, and the clinical picture is dramatically different at each level.
- Silent carrier (1 gene deleted). You have three working alpha-globin genes, which is nearly a full set. Red blood cells are normal or only slightly small. There are no symptoms, and most people never find out they carry it unless they do genetic testing.
- Alpha thalassemia trait (2 genes deleted). The two missing genes can sit on the same chromosome or on opposite chromosomes, a distinction that matters enormously for family planning. You may have mildly small red blood cells and slightly low hemoglobin, but you generally feel fine. This form is often discovered incidentally on a routine blood count.
- Hemoglobin H disease (3 genes deleted). With only one working gene, the body can’t make enough alpha-globin. Excess beta-globin chains clump together into an abnormal form called Hemoglobin H. This causes moderate to severe anemia, an enlarged spleen, jaundice, and sometimes gallstones. Symptoms can worsen during infections or pregnancy.
- Hemoglobin Bart hydrops fetalis (4 genes deleted). The most severe form. Without any alpha-globin, the fetus cannot make functional hemoglobin after the earliest weeks of development. This typically leads to severe fluid buildup (hydrops) and, without intervention, death before or shortly after birth.
Symptoms Across Severity Levels
If you’re a silent carrier or have the trait, you’ll likely never notice anything. Some trait carriers have mildly low energy during pregnancy or periods of physical stress, but many live their entire lives without a diagnosis.
Hemoglobin H disease is where symptoms become part of daily life. Chronic anemia means ongoing fatigue, paleness, and shortness of breath with exertion. The spleen works overtime breaking down defective red blood cells, so it gradually enlarges. Jaundice, a yellowish tint to the skin and eyes, can come and go. Some people with HbH disease need occasional blood transfusions during illness, surgery, or pregnancy, while others manage without regular transfusions.
Bart hydrops fetalis causes profound anemia in the developing fetus. The heart compensates by pumping harder, fluid accumulates throughout the body, and the liver and spleen enlarge dramatically. Pregnant individuals carrying an affected fetus also face serious complications, including severe preeclampsia.
How It’s Diagnosed
Alpha thalassemia is often first suspected from a routine complete blood count. Two values stand out: mean corpuscular volume (MCV), which measures red blood cell size, and mean corpuscular hemoglobin (MCH), which reflects how much hemoglobin each cell carries. In carriers and trait, MCV typically drops below 80 fL and MCH below 27 pg, meaning the cells are small and pale.
The tricky part is that iron deficiency anemia looks similar on a basic blood test. Both conditions cause small, pale red blood cells. One quick screening tool is the Mentzer index: divide MCV by the red blood cell count. A result below 13 suggests thalassemia, while a result above 13 points toward iron deficiency. In thalassemia, the body still produces plenty of red blood cells, they’re just undersized. In iron deficiency, the body makes fewer cells overall.
To confirm alpha thalassemia specifically, genetic testing (DNA analysis) is needed. A standard hemoglobin electrophoresis test can detect Hemoglobin H but often misses silent carriers and trait carriers because their hemoglobin pattern looks nearly normal. That’s why genetic testing is the gold standard, particularly when family planning is a concern.
Why the Genetic Pattern Matters for Families
If both parents carry alpha thalassemia trait, the risk to their children depends on whether each parent’s two deleted genes are on the same chromosome or on different chromosomes. When both deletions sit on the same chromosome (called cis configuration, common in Southeast Asian populations), a parent can pass along a chromosome with zero working genes. If both parents carry this pattern, there’s a 25% chance in each pregnancy that the baby inherits no functional alpha-globin genes at all, resulting in Bart hydrops fetalis.
When the deletions are on separate chromosomes (trans configuration, more common in people of African descent), each chromosome still has one working gene. A parent in this situation cannot pass along a chromosome with zero genes, so Bart hydrops fetalis doesn’t occur, though children can still inherit the trait.
Couples identified as high risk can pursue prenatal diagnosis. Chorionic villus sampling can be done between 10 and 14 weeks of pregnancy, while amniocentesis is available after 16 weeks. Both tests analyze fetal DNA to determine how many alpha-globin genes are functional.
Treatment for Hemoglobin H Disease
Most people with HbH disease don’t need regular transfusions but may need them during acute drops in hemoglobin triggered by infection, fever, or certain medications. Folic acid supplementation is common because the body uses more of it when red blood cell turnover is high.
Even without regular transfusions, iron overload can develop over time. The body absorbs more iron from food when it’s chronically anemic. Doctors monitor iron stores with blood tests, and when ferritin levels rise above 800 micrograms per liter, that’s generally the threshold where iron chelation therapy is recommended. The goal is to prevent iron from accumulating in the liver, heart, and endocrine glands, where it causes long-term organ damage. If levels climb above 1,500 after six months of treatment with less than a 15% drop, the dose is typically increased.
People with more severe HbH disease who do need regular transfusions follow a similar monitoring schedule, but iron accumulates faster, so chelation often starts earlier.
Survival in Bart Hydrops Fetalis
Bart hydrops fetalis was historically considered uniformly fatal. That’s no longer true. Research from UCSF has shown that fetuses who receive at least two in-utero blood transfusions have excellent survival rates, with resolution of hydrops, delivery near or at full term, and normal neurodevelopmental outcomes. The first transfusion is typically given around 24 weeks of gestation, and hydrops resolves on average within about four weeks.
Children who survive require lifelong blood transfusions after birth, similar to the management of other severe thalassemia forms. The decision to pursue fetal transfusions is deeply personal, and genetic counselors and fetal medicine specialists walk families through the options, long-term commitments, and expected outcomes.
Newer Treatment Options
A medication called luspatercept has shown promising results in the first large-scale clinical trial specifically for alpha thalassemia. It works by helping the body mature red blood cells more effectively. In adults who didn’t need regular transfusions, it produced a meaningful hemoglobin increase of at least 1 g/dL sustained over 12 weeks. In adults who were transfusion-dependent, it reduced transfusion needs by at least 50%. These results are notable because most thalassemia therapies were developed and tested primarily in beta thalassemia, leaving alpha thalassemia patients with fewer targeted options.